Fedora Pharmaceuticals Inc.
Developing a second-generation beta-lactamase inhibitor
This article was originally published in Start Up
In recent decades, both gram-positive and gram-negative bacteria previously susceptible to beta-lactam antibiotics have developed enzymes that render them inactive. Fedora Pharmaceuticals Inc. believes it has identified compounds that may prove able to thwart all four classes of beta-lactamases. Its compounds are meant to be used in combination with existing beta-lactam antibiotics that were historically effective but are no longer.
You may also be interested in...
The classic approach to treating bacterial infection has been to “kill the bug.” But instead of seeking only to destroy bacteria, Arsanis Biosciences GMBH intends also to neutralize certain toxins, or virulence factors, released by bacteria. The start-up is preparing a mixture of monoclonal antibodies that it believes will help patients recover from severe infections by addressing the disease state at multiple levels. While the company intends for certain of its antibodies to make bacteria more visible to phagocytes, cells whose primary function is to chew up intruders, it expects other antibodies to mitigate inflammation that is a normal but ultimately unhelpful reaction to infection.
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.